Trade Guardion Health Sciences, Inc. - GHSI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading сonditions
| Spread | 0.3780 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 7.981 |
| Open* | 7.981 |
| 1-Year Change* | 37.55% |
| Day's Range* | 7.931 - 7.981 |
| 52 wk Range | 4.66-8.25 |
| Average Volume (10 days) | 1,450.00 |
| Average Volume (3 months) | 57.16K |
| Market Cap | 6.66M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 1.28M |
| Revenue | 12.04M |
| EPS | -8.20 |
| Dividend (Yield %) | N/A |
| Beta | 0.86 |
| Next Earnings Date | Apr 15, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 7.9810 | -0.0300 | -0.37% | 8.0110 | 8.0310 | 7.9310 |
| Apr 19, 2024 | 7.9310 | 0.2000 | 2.59% | 7.7310 | 7.9410 | 7.7310 |
| Apr 18, 2024 | 7.9410 | 0.1000 | 1.28% | 7.8410 | 7.9710 | 7.8410 |
| Apr 17, 2024 | 7.8310 | 0.0000 | 0.00% | 7.8310 | 7.9310 | 7.7310 |
| Apr 16, 2024 | 7.8310 | 0.1000 | 1.29% | 7.7310 | 7.8610 | 7.7310 |
| Apr 15, 2024 | 7.7310 | 0.0000 | 0.00% | 7.7310 | 7.7410 | 7.7310 |
| Apr 12, 2024 | 7.8810 | 0.0500 | 0.64% | 7.8310 | 8.0810 | 7.7310 |
| Apr 11, 2024 | 8.0810 | 0.3000 | 3.86% | 7.7810 | 8.0810 | 7.7310 |
| Apr 10, 2024 | 7.7810 | 0.1400 | 1.83% | 7.6410 | 8.3010 | 7.5310 |
| Apr 9, 2024 | 7.6310 | -0.2900 | -3.66% | 7.9210 | 8.0210 | 7.3810 |
| Apr 8, 2024 | 8.8710 | 0.0700 | 0.80% | 8.8010 | 8.9810 | 8.8010 |
| Apr 5, 2024 | 8.8010 | 0.0500 | 0.57% | 8.7510 | 9.0010 | 8.6810 |
| Apr 4, 2024 | 8.7410 | -0.2600 | -2.89% | 9.0010 | 9.0310 | 8.7310 |
| Apr 3, 2024 | 8.9410 | -0.0900 | -1.00% | 9.0310 | 9.0310 | 8.9010 |
| Apr 2, 2024 | 8.9510 | 0.0100 | 0.11% | 8.9410 | 8.9510 | 8.9010 |
| Apr 1, 2024 | 8.9410 | -0.0100 | -0.11% | 8.9510 | 9.1710 | 8.9010 |
| Mar 28, 2024 | 8.9510 | 0.0400 | 0.45% | 8.9110 | 9.0310 | 8.9010 |
| Mar 27, 2024 | 8.9110 | 0.0100 | 0.11% | 8.9010 | 8.9110 | 8.9010 |
| Mar 26, 2024 | 8.9610 | 0.0000 | 0.00% | 8.9610 | 9.0610 | 8.9210 |
| Mar 25, 2024 | 8.9110 | 0.0100 | 0.11% | 8.9010 | 8.9810 | 8.9010 |
Guardion Health Sciences, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, May 13, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 Guardion Health Sciences Inc Earnings Release Q1 2024 Guardion Health Sciences Inc Earnings ReleaseForecast -Previous - |
| Monday, August 12, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 Guardion Health Sciences Inc Earnings Release Q2 2024 Guardion Health Sciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 11.0498 | 7.23312 | 1.88984 | 0.90294 | 0.94215 |
| Revenue | 11.0498 | 7.23312 | 1.88984 | 0.90294 | 0.94215 |
| Cost of Revenue, Total | 6.52939 | 4.12268 | 1.3307 | 0.34132 | 0.39818 |
| Gross Profit | 4.52038 | 3.11044 | 0.55914 | 0.56162 | 0.54397 |
| Total Operating Expense | 28.4704 | 31.9799 | 10.4416 | 11.3999 | 7.08587 |
| Selling/General/Admin. Expenses, Total | 11.5889 | 13.476 | 8.87082 | 9.26249 | 6.19334 |
| Research & Development | 0.1938 | 0.02625 | 0.12513 | 0.16131 | 0.19732 |
| Depreciation / Amortization | 0.05879 | 0.09158 | 0.06548 | 0.07124 | 0.29704 |
| Unusual Expense (Income) | 10.0995 | 14.2634 | 0.04945 | 1.56352 | |
| Operating Income | -17.4206 | -24.7468 | -8.55174 | -10.4969 | -6.14372 |
| Interest Income (Expense), Net Non-Operating | 0.15257 | 0.0018 | -0.00727 | -0.25837 | -1.62369 |
| Other, Net | 2.3458 | 0 | -0.01266 | -0.12301 | |
| Net Income Before Taxes | -14.9222 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Net Income After Taxes | -14.9222 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Net Income Before Extra. Items | -14.9222 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Net Income | -14.9222 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Total Adjustments to Net Income | -0.94159 | 0 | |||
| Income Available to Common Excl. Extra. Items | -15.8638 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Income Available to Common Incl. Extra. Items | -15.8638 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Diluted Net Income | -15.8638 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Diluted Weighted Average Shares | 1.121 | 0.47377 | 0.28514 | 0.12156 | 0.0673 |
| Diluted EPS Excluding Extraordinary Items | -14.1515 | -52.2298 | -30.0615 | -89.4892 | -115.42 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -5.14208 | -22.1237 | -29.8881 | -76.6271 | -115.42 |
| Other Operating Expenses, Total | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 2.78982 | 3.18569 | 2.72639 | 2.66355 | 3.27521 |
| Revenue | 2.78982 | 3.18569 | 2.72639 | 2.66355 | 3.27521 |
| Cost of Revenue, Total | 1.54055 | 1.85039 | 1.79019 | 1.57537 | 1.87567 |
| Gross Profit | 1.24927 | 1.3353 | 0.9362 | 1.08818 | 1.39954 |
| Total Operating Expense | 3.80246 | 4.6497 | 14.076 | 4.40294 | 4.98679 |
| Selling/General/Admin. Expenses, Total | 2.18471 | 2.73658 | 2.1884 | 2.75809 | 3.0156 |
| Research & Development | 0.0772 | 0.06273 | 0.03138 | 0.0602 | 0.09552 |
| Operating Income | -1.01264 | -1.46401 | -11.3496 | -1.73939 | -1.71158 |
| Interest Income (Expense), Net Non-Operating | 0.09554 | 0.099 | 0.09811 | 0.04328 | 0.00962 |
| Net Income Before Taxes | -1.17241 | 0.53309 | -8.90567 | -1.69611 | -1.70196 |
| Net Income After Taxes | -1.17241 | 0.53309 | -8.90567 | -1.69611 | -1.70196 |
| Net Income Before Extra. Items | -1.17241 | 0.53309 | -8.90567 | -1.69611 | -1.70196 |
| Net Income | -1.17241 | 0.53309 | -8.90567 | -1.69611 | -1.70196 |
| Income Available to Common Excl. Extra. Items | -1.17241 | 0.53309 | -9.84725 | -1.69611 | -1.70196 |
| Income Available to Common Incl. Extra. Items | -1.17241 | 0.53309 | -9.84725 | -1.69611 | -1.70196 |
| Diluted Net Income | -1.17241 | 0.53309 | -9.84725 | -1.69611 | -1.70196 |
| Diluted Weighted Average Shares | 1.26734 | 1.26734 | 1.23223 | 1.23202 | 1.23106 |
| Diluted EPS Excluding Extraordinary Items | -0.9251 | 0.42064 | -7.99141 | -1.3767 | -1.38252 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.9251 | 0.42064 | 0.17752 | -1.36916 | -1.38252 |
| Unusual Expense (Income) | 0 | 0 | 10.066 | 0.00929 | 0 |
| Other Operating Expenses, Total | |||||
| Other, Net | -0.2553 | 1.8981 | 2.3458 | ||
| Total Adjustments to Net Income | -0.94159 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 21.6372 | 12.0692 | 9.09488 | 11.8677 | 1.10492 |
| Cash and Short Term Investments | 15.9055 | 9.08955 | 8.51873 | 11.1155 | 0.67095 |
| Cash | 4.09393 | 8.51873 | 11.1155 | 0.67095 | |
| Total Receivables, Net | 1.92435 | 1.41157 | 0.01125 | 0.07834 | 0.0282 |
| Accounts Receivable - Trade, Net | 1.92435 | 1.41157 | 0.01125 | 0.07834 | 0.0282 |
| Total Inventory | 3.11942 | 0.36769 | 0.38497 | 0.31094 | 0.358 |
| Prepaid Expenses | 0.68793 | 1.20038 | 0.17993 | 0.36294 | 0.04777 |
| Total Assets | 21.6861 | 23.4606 | 9.8609 | 12.8768 | 3.6811 |
| Property/Plant/Equipment, Total - Net | 0.04887 | 0.13564 | 0.70427 | 0.94735 | 0.2748 |
| Property/Plant/Equipment, Total - Gross | 0.17613 | 0.27196 | |||
| Accumulated Depreciation, Total | -0.12726 | -0.13633 | |||
| Other Long Term Assets, Total | 0 | 0.01175 | 0.01175 | 0.28175 | |
| Total Current Liabilities | 4.01155 | 1.15905 | 1.07373 | 0.41023 | 0.49534 |
| Accounts Payable | 1.51805 | 0.24135 | 0.60831 | 0.12913 | 0.41393 |
| Accrued Expenses | 0.56209 | 0.9177 | 0.29048 | 0.26778 | 0.08141 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 1.9314 | 0 | 0.17494 | 0.01332 | 0 |
| Total Liabilities | 8.51815 | 1.16285 | 1.34563 | 0.84498 | 0.49534 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Total Equity | 13.1679 | 22.2978 | 8.51527 | 12.0318 | 3.18576 |
| Preferred Stock - Non Redeemable, Net | 5.25 | 0 | 0 | 0 | |
| Common Stock | 0.00127 | 0.02443 | 0.01517 | 0.07498 | 0.02056 |
| Additional Paid-In Capital | 101.641 | 101.075 | 62.5834 | 57.4685 | 37.7986 |
| Retained Earnings (Accumulated Deficit) | -93.7243 | -78.8021 | -54.0833 | -45.5117 | -34.6334 |
| Total Liabilities & Shareholders’ Equity | 21.6861 | 23.4606 | 9.8609 | 12.8768 | 3.6811 |
| Total Common Shares Outstanding | 1.26734 | 0.48854 | 0.30341 | 0.24994 | 0.06855 |
| Goodwill, Net | 0 | 1.56352 | |||
| Intangibles, Net | 0 | 11.2558 | 0.05 | 0.05 | 0.4561 |
| Other Liabilities, Total | 4.5066 | 0.00381 | 0.2719 | 0.43475 | |
| Short Term Investments | 0 | 4.99562 | |||
| Cash & Equivalents | 15.9055 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 12.8396 | 13.431 | 14.373 | 21.6372 | 17.8111 |
| Cash and Short Term Investments | 7.65731 | 8.36599 | 8.77463 | 15.9055 | 12.946 |
| Cash | |||||
| Total Receivables, Net | 1.76603 | 1.55514 | 1.94675 | 1.92435 | 1.87374 |
| Accounts Receivable - Trade, Net | 1.76603 | 1.55514 | 1.94675 | 1.92435 | 1.87374 |
| Total Inventory | 2.45065 | 2.513 | 3.06092 | 3.11942 | 1.95293 |
| Prepaid Expenses | 0.96564 | 0.9969 | 0.5907 | 0.68793 | 1.03844 |
| Total Assets | 12.8778 | 13.4741 | 14.4187 | 21.6861 | 28.2282 |
| Property/Plant/Equipment, Total - Net | 0.03814 | 0.04304 | 0.04573 | 0.04887 | 0.05376 |
| Property/Plant/Equipment, Total - Gross | 0.17613 | 0.17629 | |||
| Accumulated Depreciation, Total | -0.12726 | -0.12253 | |||
| Intangibles, Net | 0 | 10.3633 | |||
| Other Long Term Assets, Total | |||||
| Total Current Liabilities | 1.43166 | 1.99653 | 2.178 | 4.01155 | 1.73323 |
| Accounts Payable | 0.8816 | 0.98532 | 0.88857 | 1.51805 | 1.0406 |
| Accrued Expenses | 0.55006 | 0.4525 | 0.50873 | 0.56209 | 0.69263 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.5587 | 0.7807 | 1.9314 | |
| Total Liabilities | 5.17606 | 6.23303 | 5.9372 | 8.51815 | 1.73323 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.7444 | 4.2365 | 3.7592 | 4.5066 | 0 |
| Total Equity | 7.70172 | 7.24105 | 8.48152 | 13.1679 | 26.495 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 5.25 | 0 |
| Common Stock | 0.00128 | 0.00127 | 0.00127 | 0.00127 | 0.0616 |
| Additional Paid-In Capital | 101.691 | 101.603 | 101.671 | 101.641 | 111.252 |
| Retained Earnings (Accumulated Deficit) | -93.991 | -94.3636 | -93.1912 | -93.7243 | -84.8186 |
| Total Liabilities & Shareholders’ Equity | 12.8778 | 13.4741 | 14.4187 | 21.6861 | 28.2282 |
| Total Common Shares Outstanding | 1.27524 | 1.26734 | 1.26734 | 1.26734 | 1.23202 |
| Short Term Investments | 0 | 0 | |||
| Goodwill, Net | |||||
| Cash & Equivalents | 7.65731 | 8.36599 | 8.77463 | 15.9055 | 12.946 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.9222 | -24.745 | -8.57166 | -10.8783 | -7.76741 |
| Cash From Operating Activities | -7.44681 | -10.6444 | -8.01393 | -6.03 | -4.17383 |
| Cash From Operating Activities | 1.24879 | 0.78292 | 0.06548 | 0.47735 | 0.29567 |
| Non-Cash Items | 8.11917 | 13.7546 | 0.79114 | 4.8027 | 3.21643 |
| Changes in Working Capital | -1.89255 | -0.43689 | -0.29889 | -0.43174 | 0.08147 |
| Cash From Investing Activities | 4.99005 | -31.0114 | -0.03473 | -0.17108 | -0.31024 |
| Capital Expenditures | -0.00557 | -0.07459 | -0.04073 | -0.17108 | -0.31024 |
| Cash From Financing Activities | 14.2683 | 37.231 | 5.45189 | 16.6456 | 0.41979 |
| Financing Cash Flow Items | 0 | -0.41613 | |||
| Issuance (Retirement) of Stock, Net | 14.2683 | 37.231 | 5.45189 | 16.3962 | 0.86646 |
| Issuance (Retirement) of Debt, Net | 0.24945 | -0.03054 | |||
| Net Change in Cash | 11.8116 | -4.42481 | -2.59677 | 10.4445 | -4.06428 |
| Other Investing Cash Flow Items, Total | 4.99562 | -30.9368 | 0.006 | 0 | |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Cash Interest Paid | 0 | 0 | 0.00727 | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 0.53309 | -14.9222 | -6.01656 | -4.32045 | -2.61849 |
| Cash From Operating Activities | -1.87921 | -7.44681 | -6.08291 | -4.80077 | -2.22647 |
| Cash From Operating Activities | 0.00479 | 1.24879 | 0.9464 | 0.63418 | 0.31705 |
| Non-Cash Items | -1.86759 | 8.11917 | 0.30236 | 0.24353 | 0.17013 |
| Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Changes in Working Capital | -0.5495 | -1.89255 | -1.31511 | -1.35802 | -0.09516 |
| Cash From Investing Activities | -0.00165 | 4.99005 | 4.99005 | -5.01354 | -7.00392 |
| Capital Expenditures | -0.00165 | -0.00557 | -0.00557 | -0.0024 | -0.0024 |
| Cash From Financing Activities | -5.25 | 14.2683 | 9.94493 | 9.94493 | 9.96894 |
| Issuance (Retirement) of Stock, Net | -5.25 | 14.2683 | 9.96894 | 9.96894 | 9.96894 |
| Net Change in Cash | -7.13086 | 11.8116 | 8.85208 | 0.13062 | 0.73854 |
| Other Investing Cash Flow Items, Total | 0 | 4.99562 | 4.99562 | -5.01114 | -7.00152 |
| Financing Cash Flow Items | -0.02401 | -0.02401 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Guardion Health Sciences, Inc. Company profile
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.| Industry: | Pharmaceuticals (NEC) |
2925 Richmond Avenue
Suite 1200
HOUSTON
TEXAS 77098
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com